Quality assessment of dyslipidemia in managed care: Current best evidence should be used to benchmark quality

Annals of Pharmacotherapy

Volumn 40, Issue 1, 2006, Pages 124-127

  Nair, Kavita V ^a   Saseen, Joseph J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Dyslipidemia; Managed care; Performance measure

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

DYSLIPIDEMIA; EDUCATION PROGRAM; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEART PROTECTION; HUMAN; MANAGED CARE; MEASUREMENT; PERFORMANCE MEASUREMENT SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; SHORT SURVEY;

ADULT; BENCHMARKING; CHOLESTEROL, LDL; DYSLIPIDEMIAS; EFFICIENCY, ORGANIZATIONAL; EVIDENCE-BASED MEDICINE; HUMANS; MANAGED CARE PROGRAMS; QUALITY INDICATORS, HEALTH CARE;

EID: 32344435207     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G143     Document Type: Short Survey

References (18)

1. Roper WL, Hodlewsky TR, Tilson H, Lohr KN, Campbell WH. The potential impact of measuring healthcare quality on pharmaceutical related costs and outcomes. Dis Manag Health Outcomes 2002;10:233-9.
2. Eddy DM. Performance measurement: problems and solutions. Health Affairs 1998;17:7-25.
3. Jacobson TA. Reaching National Cholesterol Education Program goals: a managed care approach to improving hyperlipidemia disease management outcomes. Introduction. Am J Med 2001;110(suppl 6A):1S-2S.
4. Lee TH, Cleeman JI, Grundy SM, et al. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA 2000;283:94-8.
5. Kerr EA, McGlynn EA, Van Vorst KA, Wickstrom SL. Measuring antidepressant prescribing practice in a health care system using administrative data. J Qual Improve 2000;26:203-16.
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. Grundy SM, Cleeman JI, Merz NM, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
8. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003;361:1149-58.
9. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
10. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
11. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo controlled trial. Lancet 2002;360:7-22.
13. Latts LM. Assessing the results: Phase 1 hyperlipidemia outcomes in 27 health plans. Am J Med 2001;110:17S-23S.
14. National Committee on Quality Assurance. 2004 State of Health Care Quality. Washington, DC. www.ncqa.org/commumcations/SOMC/SOHC2004. pdf (accessed 2005 Jul 3).
15. Cholesterol management after a heart attack. In: The State of Healthcare Quality 2004. National Committee on Quality Assurance, www.ncqa.org/ communications/sohc2004/cholesterol_management.htm (accessed 2005 Jul 2).
16. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9.
17. Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005;11:306-12.
18. Quilliam BJ, Perez HE, Andros V, Jones P. Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. J Manag Care Pharm 2004;10:244-50.